Market Research and Forecast of Antineoplastic Drugs in China 2016-2021 - Market will Reach More than RMB250 Billion - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Market Research and Forecast of Antineoplastic Drugs in China 2016-2021" report to their offering.

Antineoplastic drugs developed from traditional single antineoplastic drug towards a new type of antineoplastic drugs aiming at functions at multiple links. Research and development of antineoplastic drugs have stepped in to a new stage.

Till now, there is nearly four million cases of new tumors in China every year. With the aging of population, environmental pollution caused by industrialization and lifestyles changed by factors like urbanization, malignant tumors replace cardiovascular diseases and become the top killer in China, taking 25% in total deaths.

For the increasing incidence of tumors, released needs for antineoplastic drugs and improving technologies for the drugs, output of the drugs will further increase in China. According to statistics, in 2015, the total output of antineoplastic drugs was about 440 tonnes, with the market scale of nearly RMB100 billion. Sales of transnational enterprises were more centered and generally focused on promotion of their key products. While domestic enterprises applied the strategy of sales in a wide range.

In 2021, the forecast of China's antineoplastic drug market will reach more than RMB250 billion, which is relatively conservative compared to the global market. Except adjuvant drugs like immunosuppressant, anti-metabolic will have the most market shares, with a stable growth. The second will be botanical preparations, remaining at a relatively fast growth. Growth of alkylating agents, antibiotics and platinum drugs will tend to be slow. As for targeted drugs, it is predicted that there is a large potential in the independent R&D of targeted drugs, with the consideration of more supports by the government, and which will become the most important field leading the domestic market of antineoplastic drugs.

Key Topics Covered:

1 Overview of China Antineoplastic Drug Industry

1.1 Tumors in China

1.2 Supply and Demand

1.3 Competition Structure of China Antineoplastic Drug Industry

2 Sales Channels of Antineoplastic Drugs in China in 2015

2.1 Hospitals

2.2 Drugstores

3 Analysis of Major Companies of Antineoplastic Drugs in China

3.1 Jiangsu Hengrui Medicine Co., Ltd.

3.2 China Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC)

3.3 Guizhou Yibai Pharmaceutical Co., Ltd.

3.4 Zhejiang HISUN Pharmaceutical Co., Ltd.

3.5 Beijing SL Pharmaceutical Co., Ltd.

3.6 Jiangsu Aosaikang Pharmaceutical Co., Ltd.

4 Analysis of Antineoplastic Drugs by Subdivisions

4.1 Paclitaxel

4.2 Docetaxel

4.3 Pemetrexed

4.4 Tegafur, Gimeracil and Oteracil Potassium

5 Forecast of Antineoplastic Drug Industry in China, 2016-2021

6 Analysis of Investment and Financing Strategy Plan of Antineoplastic Drug Industry in China

6.1 Conclusion of Antineoplastic Drugs in China

6.2 Suggestions on Strategy Planning

For more information about this report visit http://www.researchandmarkets.com/research/bsnw2j/market_research

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs